Supplemental Material

Table S1. Adjusted* HR (95% CI) for the primary CVD endpoint among those achieving an absolute reduction greater than or less than the median on rosuvastatin 20 mg daily relative to placebo (reference), examining event rates after 1 year among those confirmed to be on-statin (N= 8,420; 130 events) compared with the overall cohort.

Marker	Regression Model	HR (95% CI)			P-value**
		Placebo	Rosuvastatin		
			Minimal Response (<median abs. Δ)	Larger Response (≥ median abs. Δ)	
LDL-c	Confirmed on study drug	ref.	0.69 (0.43, 1.12)	0.59 (0.38, 0.93)	0.62
	Overall	ref.	0.74 (0.52, 1.06)	0.54 (0.36, 0.79)	0.17
Triglycerides	Confirmed on study drug	ref.	0.50 (0.29, 0.85)	0.75 (0.49, 1.16)	0.19
	Overall	ref.	0.54 (0.37, 0.80)	0.72 (0.51, 1.03)	0.24
Calculated RC	Confirmed on study drug	ref.	0.50 (0.30, 0.85)	0.75 (0.49, 1.15)	0.20
	Overall	ref.	0.56 (0.38, 0.83)	0.71 (0.50, 1.00)	0.35
VLDL-c	Confirmed on study drug	ref.	0.78 (0.49, 1.23)	0.52 (0.32, 0.85)	0.20
	Overall	ref.	0.86 (0.61, 1.21)	0.44 (0.30, 0.67)	0.01
Large VLDL-p	Confirmed on study drug	ref.	0.73 (0.39, 1.38)	0.73 (0.38, 1.39)	0.98
	Overall	ref.	0.47 (0.29, 0.75)	0.45 (0.27, 0.73)	0.85
Medium VLDL-p	Confirmed on study drug	ref.	0.60 (0.38, 0.97)	0.66 (0.42, 1.05)	0.76
	Overall	ref.	0.59 (0.40, 0.86)	0.68 (0.47, 0.97)	0.56
Small VLDL-p	Confirmed on study drug	ref.	0.79 (0.50, 1.25)	0.51 (0.31, 0.83)	0.16
	Overall	ref.	0.86 (0.61, 1.21)	0.46 (0.31, 0.68)	0.01

Abbreviations: CI = confidence interval; HR = hazard ratio; RC = remnant cholesterol; VLDL=very low-density cholesterol.
*Adjusted model is adjusted for age, sex, race, smoking, baseline BMI, baseline systolic BP, baseline fasting glucose, baseline HDLc, the natural log of baseline hsCRP, and baseline marker level. **For comparison of hazard ratio between the two rosuvastatin groups.
**P for comparison of Minimal versus Larger response groups.